146 related articles for article (PubMed ID: 20455330)
1. Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
Prescrire Int; 2010 Feb; 19(105):9-11. PubMed ID: 20455330
[TBL] [Abstract][Full Text] [Related]
2. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
3. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Bays HE; Ballantyne C
Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
[TBL] [Abstract][Full Text] [Related]
4. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
5. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
6. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
7. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
8. Nicotinic acid: new/old drug. Immediate or sustained release: too risky for a drug with no proven benefit.
Prescrire Int; 2006 Dec; 15(86):213-6. PubMed ID: 17165243
[TBL] [Abstract][Full Text] [Related]
9. Extended-release niacin (nicotinic acid)/laropiprant.
Perry CM
Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
[TBL] [Abstract][Full Text] [Related]
10. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
Markel A
Isr Med Assoc J; 2011 Jun; 13(6):368-74. PubMed ID: 21809737
[TBL] [Abstract][Full Text] [Related]
11. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
[TBL] [Abstract][Full Text] [Related]
13. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
14. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage.
Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698
[TBL] [Abstract][Full Text] [Related]
16. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Lauring B; Dishy V; Luo WL; Laterza O; Patterson J; Cote J; Chao A; Larson P; Gutierrez M; Wagner JA; Lai E
J Clin Pharmacol; 2009 Dec; 49(12):1426-35. PubMed ID: 19833861
[TBL] [Abstract][Full Text] [Related]
17. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
[TBL] [Abstract][Full Text] [Related]
18. New perspectives on the use of niacin in the treatment of lipid disorders.
McKenney J
Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
[TBL] [Abstract][Full Text] [Related]
19. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
Carlson LA
J Intern Med; 2005 Aug; 258(2):94-114. PubMed ID: 16018787
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]